Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-06-06
1997-09-09
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142282, 5142305, 5142308, 514249, 514258, 514259, 514301, 514312, 514314, 514318, 544 90, 544 91, 544 92, 544257, 544283, 544284, 544105, 544353, 544 585, 544 586, 544 582, 544350, 546158, 546157, 546165, 546112, C07D40102, C07D40302, A61K 3154, A61K 31545
Patent
active
056657196
ABSTRACT:
Compounds of the formula ##STR1## X is --O--, --NH-- and --NR.sup.8 --; Y is --CH.sub.2 --, --CHR.sup.8 -- and --C(R.sup.8).sub.2 --; R.sup.1 is camphor-10-yl, C.sub.1-5 alkoxyl, styryl, hydroxystyryl, furyl, unsubstituted or substituted thienyl, naphthyl, indolyl, tetrahydronaphthyl, unsubstituted, mono- or di-substituted pyridyl, pyrazinyl, unsubstituted or substituted cyclohexyl where the substituent is R.sup.4, and unsubstituted or substituted phenyl where the substituents on phenyl are R.sup.5, R.sup.6 and R.sup.7 ; R.sup.2 is hydrogen, C.sub.1-5 alkoxy, C.sub.1-5 alkyl, amino, C.sub.1-5 alkylcarbonylamino, nitro or halogen; R.sup.3 is hydrogen, C.sub.1-5 alkoxycarbonyl, cyano or carbamoyl; R.sup.4 is one to two of hydrogen, oxo, hydroxy, C.sub.1-5 alkoxy, C.sub.1-5 alkoxycarbonylamino-C.sub.1-5 alkyl and amino-C.sub.1-5 alkyl; R.sup.5, R.sup.6 are each independently selected from hydrogen, halogen, C.sub.1-5 alkyl, hydroxyl and C.sub.1-5 alkoxy; R.sup.7 is ##STR2## W is CO or SO.sub.2 ; and m is an integer from 0 to 1. Such compounds as useful as oxytocin and vasopressin receptor antagonists.
REFERENCES:
patent: 4087425 (1978-05-01), Garcia et al.
patent: 4147870 (1979-04-01), Garcia et al.
patent: 4344945 (1982-08-01), Teranishi et al.
patent: 5091387 (1992-02-01), Evans et al.
patent: 5204349 (1993-04-01), Bock et al.
patent: 5225402 (1993-07-01), Ogawa et al.
patent: 5300513 (1994-04-01), Ogawa et al.
patent: 5356904 (1994-10-01), Freidinger et al.
patent: 5436254 (1995-07-01), Ogawa et al.
Klein et al., Chemical Abstracts, vol. 81, AB. No. 81:77, 786r (1974).
Klein et al., Chemical Abstracts, vol. 84, AB. No. 84:105,358 (1976).
Takai et al., Chemical and Pharmaceutical Bulletin, vol. 33, No. 3, (1985).
Kyowa Hakko Kogyo Co. Ltd., Chemical Abstracts, vol. 98, AB No. 98:179,406k, (1983) JP 57,192,383 (1982).
Kyowa Hakko Kogyo Co. Ltd., Chemical Abstracts, vol. 97, AB No. 97:182,449m, JP 82,59,889 (1982).
Lobbezoo, et al., Journal of Medicinal Chemistry, vol. 24, No. 7, pp. 777-782 (1981).
Ogawa, et al., Journal of Medicinal Chemistry, vol. 36, No. 14, pp. 2011-2017 (1993).
Yamamura, et al., Science, vol. 252, No. 5005, pp. 572-574 (1991).
J. Pharm. Exp. Ther., vol. 264, No. 1, pp. 308-314, by Pettibone et al., entitled Identification of an Orally Active, Nonpeptidyl Oxytocin Antagonist, 1985.
J. Med. Chem., vol. 35, No. 21, pp. 3919-3927, by Evans et al., entitled Orally Active, Nonpeptide Oxytocin Antagonists, 1978.
Chemical abstracts, Vo. 78, No. 5, 5 Feb. 1973, abstract No. 29818u, p. 510, col. L.
Chemical abstracts, vol. 86, No. 5, 31 Jan. 1977, abstract No. 29877c p. 376, col. R.
Anderson Paul S.
Bock Mark G.
Evans Ben E.
Freidinger Roger M.
Hobbs Doug W.
Appollina Mary A.
Grumbling Matthew V.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytoc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytoc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytoc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-70161